WilmerHale Advises Underwriters in TCR² Therapeutics’ IPO

WilmerHale Advises Underwriters in TCR² Therapeutics’ IPO

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the joint-book running managers in the initial public offering of 5,750,000 shares of common stock of TCR² Therapeutics Inc., reflecting the full exercise of the underwriters’ option to purchase additional shares, for aggregate gross proceeds of $86.25 million. The offering priced on February 13, 2019 at $15.00 per share and closed on February 19, 2019, and the option shares closed on February 26, 2019.

The WilmerHale team included Lisa Firenze, Scott Lunin, Emily Gainor, Sean Linnehan, Alex Dzioba, Erin Garrity, Bruce Manheim, Colleen Superko and Heidi Treiber.


Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel